Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - artemether, quantity: 20 mg; lumefantrine, quantity: 120 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; crospovidone; saccharin sodium; hypromellose; magnesium stearate; polysorbate 80; colloidal anhydrous silica; flavour - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet dispersible tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in children and infants weighing between 5kg and less than 35kg.

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artemether ph.int. and lumefantrine - tablet - each uncoated tablet contains: artemether… - artemether and lumefantrine

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - lumefantrine, quantity: 120 mg; artemether, quantity: 20 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; croscarmellose sodium; hypromellose - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in patients aged at least 12 years and weighing at least 35kg.

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artemether and lumefantrine tablets 20/120mg - tablet - artemether ph int - 20mg, lumefantrine 120mg - antimalarial antiprotozoals: combinations of

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

ipca laboratories limited, india - artemether , lumefantrine - dispersible tablets - artemether ph int. 20 & lumefantrine ph. int. 120

United States - English - NLM (National Library of Medicine)

central texas community health centers - artemether (unii: c7d6t3h22j) (artemether - unii:c7d6t3h22j), lumefantrine (unii: f38r0jr742) (lumefantrine - unii:f38r0jr742) - artemether 20 mg - coartem (artemether/lumefantrine) tablets are indicated for treatment of acute, uncomplicated malaria infections due to plasmodium falciparum in patients of 5 kg bodyweight and above. coartem tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see clinical studies (14.1) ]. limitations of use : - coartem tablets are not approved for patients with severe or complicated p. falciparum malaria. - coartem tablets are not approved for the prevention of malaria. hypersensitivity - known hypersensitivity to artemether, lumefantrine, or to any of the excipients of coartem tablets [see adverse reactions (6.3)] . strong cyp3a4 inducers - coadministration of strong inducers of cyp3a4 such as rifampin, carbamazepine, phenytoin, and st. john's wort with coartem tablets can result in decreased concentrations of artemether and/or lumefantrine and loss of antimalarial efficacy [see warnings and precautions (5.3), drug interactions (7.1), and clinical pharmacolo

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - artemether (unii: c7d6t3h22j) (artemether - unii:c7d6t3h22j), lumefantrine (unii: f38r0jr742) (lumefantrine - unii:f38r0jr742) - artemether 20 mg - coartem tablets are indicated for treatment of acute, uncomplicated malaria infections due to plasmodium falciparum (p. falciparum) in patients 2 months of age and older with a bodyweight of 5 kg and above. coartem tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see clinical studies (14.1) ]. limitations of use: - coartem tablets are not approved for patients with severe or complicated p. falciparum malaria. - coartem tablets are not approved for the prevention of malaria. hypersensitivity known hypersensitivity to artemether, lumefantrine, or to any of the excipients of coartem tablets [see adverse reactions (6.2)] . strong cyp3a4 inducers coadministration of strong inducers of cyp3a4 such as rifampin, carbamazepine, phenytoin, and st. john’s wort with coartem tablets can result in decreased concentrations of artemether and/or lumefantrine and loss of antimalarial efficacy [see warnings and precautions (5.3), drug interactions (7.1), and cl

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - artemether, quantity: 20 mg; lumefantrine, quantity: 120 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; crospovidone; saccharin sodium; hypromellose; magnesium stearate; polysorbate 80; colloidal anhydrous silica; flavour - coartem dispersible tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in children and infants weighing between 5kg and less than 35kg.

Kenya - English - Pharmacy and Poisons Board

crown healthcare crownplex, mombasa road, nairobi, kenya - artemether lumefantrine - tablet - artemether 20mg and lumefantrine 120mg - antimalarial antiprotozoals: combinations of

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - artemether and lumefantrine - dispersible tablet - artemether ph. int………20 mg lumefantrine……….120 mg - artemether and lumefantrine